Walleye Capital
MREO

Walleye Capital’s Mereo BioPharma MREO Stock Holding History

Walleye Capital’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-129,629
Closed -$454K – 4794
2024
Q4 		$454K Buy
+129,629
New +$509K ﹤0.01% 3069

Other funds holding MREO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Walleye Capital's MREO Position: Q1 2025 in Review

Walleye Capital sold out of Mereo BioPharma (MREO) in Q1 2025, closing a stake of 129,629 shares — an estimated $454K sold.

Walleye Capital first reported a position in MREO in Q4 2024 and held it in 1 quarter. The position peaked at $454K in Q4 2024. 90 funds tracked by Wall St. Rank hold MREO as of Q1 2025.

  • Walleye Capital reported no remaining Mereo BioPharma position as of Q1 2025 after selling out during the quarter.
  • Walleye Capital sold 129,629 Mereo BioPharma shares in Q1 2025, an estimated $454K.
  • Walleye Capital first reported a position in Mereo BioPharma in Q4 2024 and held it in 1 quarter.
  • Walleye Capital's Mereo BioPharma position peaked at $454K in Q4 2024.
  • 90 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.